Skip to content

Ayurvedic management of Nerve Disease(e.g.numbness,burning etc.) due to Diabetes.

A Clinical Comparative study of Shilajatu Vataka and Gokshuradi Guggulu in the Management of Diabetic Polyneuropathy - SVGGDP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/12/005316
Enrollment
60
Registered
2014-12-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients having Diabetes with Neuropathy

Interventions

Intervention1: Shilajatu Vataka: Shilajatu Vataka, 500 mg, 2 tablet BD with warm water, After food x 8 wks. Control Intervention1: Gokshuradi Guggulu: Gokshuradi Guggulu, 500 mg, 2 tablet BD with warm

Sponsors

IPGT AND RA GAU
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of either sex, age group, above 40yrs and below 70yrs. 2) Metabolically stable Type 2 Diabetic with symptomatic diabetic sensorimotor polyneuropathy (DSPN) who are with or without medications (modern medications like Metformin, Thiazolidinediones, Alpha glucosidase inhibitors, Sulphonilureas, Meglitinides, Incretin etc.) 3) Both freshly detected as well as previously treated cases will be included for the study. 4) Presence of classical signs and symptoms Madhumeha. 5) Patients with Diabetic Neuropathy having N1a, N2a and N2b grading will be included for the study.

Exclusion criteria

Exclusion criteria: 1) Patient age below 40 years and above 70 years. 2) Patients with other metabolic & endocrine disorders. 3) Patients suffering from HIV, TB etc, infectious diseases. 4) Patients having any other malignancies, any other serious illnesses. 5) Patients with uncontrolled diabetes. 6) Patients with diabetic wounds / ulcers. 7) Patients with complications like Diabetic nephropathy, Diabetic keto acidosis & Diabetic coma. 8) Patients with Diabetic Neuropathy N0 and N3 will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
rather than just Timepoint: upto present study

Secondary

MeasureTime frame
rather than justTimepoint: upto present study

Countries

India

Contacts

Public ContactDr Alankruta Dave

IPGT and RA JAMNAGAR Gujarat

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026